Stock VELO VELOXIS PHARMACEUTICALS A/S
Add to a list
To use this feature you must be a member
Log inSign up

Sector Chart Veloxis Pharmaceuticals A/S

Equities

VELO

DK0060048148

Delayed Nasdaq Copenhagen
Other stock markets
 		5-day change 1st Jan Change
- DKK -.--% Intraday chart for Veloxis Pharmaceuticals A/S -.--% -0.50%
2022 Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study Evaluating T-Guard(R) in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) CI
2021 Veloxis Pharmaceuticals, Inc entered into a global license agreement to acquire Worldwide Rights to FR104 from OSE Immunotherapeutics SA. CI
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes

Sector Specialty & Advanced Pharmaceuticals

Capi. Sales growth Profitability Finances EV / Sales P/E ratio
VELOXIS PHARMACEUTICALS A/S Stock Veloxis Pharmaceuticals A/S
 1.64B - - - - -
MERCK KGAA Stock Merck KGaA
 72.94B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
 5.07B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
 4.78B - -
YUHAN CORPORATION Stock Yuhan Corporation
 3.9B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
 2.56B
  1. Stock Market
  2. Equities
  3. VELO Stock
  4. Charts Veloxis Pharmaceuticals A/S
  5. Sector Chart
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW